The main important findings obtained from the present work were that the SKP2 gene expression and protein levels were significantly upregulated in the CML patients compared to the control group; moreover, these levels were dramatically downregulated in the CML patients initially treated with IM at the early response stage. The gene discussed is SKP2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.